Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: A multiplex ligation-dependent probe amplification study

Cathy B. Moelans, Roel A. De Weger, Hanneke N. Monsuur, Anoek H J Maes, Paul J. Van Diest

Research output: Contribution to journalArticle

Abstract

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of mammographically detected breast cancers. Although DCIS is generally highly curable, some women with DCIS will develop life-threatening invasive breast cancer, but the determinants of progression to infiltrating ductal cancer (IDC) are largely unknown. In the current study, we used multiplex ligation-dependent probe amplification (MLPA), a multiplex PCR-based test, to compare copy numbers of 21 breast cancer related genes between laser-microdissected DCIS and adjacent IDC lesions in 39 patients. Genes included in this study were ESR1, EGFR, FGFR1, ADAM9, IKBKB, PRDM14, MTDH, MYC, CCND1, EMSY, CDH1, TRAF4, CPD, MED1, HER2, CDC6, TOP2A, MAPT, BIRC5, CCNE1 and AURKA. There were no significant differences in copy number for the 21 genes between DCIS and adjacent IDC. Low/intermediate-grade DCIS showed on average 6 gains/amplifications versus 8 in high-grade DCIS (p=0.158). Furthermore, alterations of AURKA and CCNE1 were exclusively found in high-grade DCIS, and HER2, PRDM14 and EMSY amplification was more frequent in high-grade DCIS than in low/intermediate-grade DCIS. In contrast, the average number of alterations in low/intermediate and high-grade IDC was similar, and although EGFR alterations were exclusively found in high-grade IDC compared to low/intermediate-grade IDC, there were generally fewer differences between low/intermediate-grade and high-grade IDC than between low/intermediate-grade and high-grade DCIS. In conclusion, there were no significant differences in copy number for 21 breast cancer related genes between DCIS and adjacent IDC, indicating that DCIS is genetically as advanced as its invasive counterpart. However, high-grade DCIS showed more copy number changes than low/intermediate-grade DCIS with specifically involved genes, supporting a model in which different histological grades of DCIS are associated with distinct genomic changes that progress to IDC in different routes. These high-grade DCIS specific genes may be potential targets for treatment and/or predict progression.

Original languageEnglish (US)
Pages (from-to)165-173
Number of pages9
JournalAnalytical Cellular Pathology
Volume33
Issue number3-4
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Multiplex Polymerase Chain Reaction
Breast Neoplasms
Neoplasms
Aurora Kinase A
Neoplasm Genes
TNF Receptor-Associated Factor 4
I-kappa B Kinase
Genes
Gene Dosage

Keywords

  • breast cancer
  • DCIS
  • IDC
  • laser microdissection
  • MLPA

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pathology and Forensic Medicine
  • Cell Biology
  • Medicine(all)

Cite this

Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma : A multiplex ligation-dependent probe amplification study. / Moelans, Cathy B.; De Weger, Roel A.; Monsuur, Hanneke N.; Maes, Anoek H J; Van Diest, Paul J.

In: Analytical Cellular Pathology, Vol. 33, No. 3-4, 2010, p. 165-173.

Research output: Contribution to journalArticle

Moelans, Cathy B. ; De Weger, Roel A. ; Monsuur, Hanneke N. ; Maes, Anoek H J ; Van Diest, Paul J. / Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma : A multiplex ligation-dependent probe amplification study. In: Analytical Cellular Pathology. 2010 ; Vol. 33, No. 3-4. pp. 165-173.
@article{8e97d3deb1244b90a475d6d8079d32c0,
title = "Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: A multiplex ligation-dependent probe amplification study",
abstract = "Ductal carcinoma in situ (DCIS) accounts for approximately 20{\%} of mammographically detected breast cancers. Although DCIS is generally highly curable, some women with DCIS will develop life-threatening invasive breast cancer, but the determinants of progression to infiltrating ductal cancer (IDC) are largely unknown. In the current study, we used multiplex ligation-dependent probe amplification (MLPA), a multiplex PCR-based test, to compare copy numbers of 21 breast cancer related genes between laser-microdissected DCIS and adjacent IDC lesions in 39 patients. Genes included in this study were ESR1, EGFR, FGFR1, ADAM9, IKBKB, PRDM14, MTDH, MYC, CCND1, EMSY, CDH1, TRAF4, CPD, MED1, HER2, CDC6, TOP2A, MAPT, BIRC5, CCNE1 and AURKA. There were no significant differences in copy number for the 21 genes between DCIS and adjacent IDC. Low/intermediate-grade DCIS showed on average 6 gains/amplifications versus 8 in high-grade DCIS (p=0.158). Furthermore, alterations of AURKA and CCNE1 were exclusively found in high-grade DCIS, and HER2, PRDM14 and EMSY amplification was more frequent in high-grade DCIS than in low/intermediate-grade DCIS. In contrast, the average number of alterations in low/intermediate and high-grade IDC was similar, and although EGFR alterations were exclusively found in high-grade IDC compared to low/intermediate-grade IDC, there were generally fewer differences between low/intermediate-grade and high-grade IDC than between low/intermediate-grade and high-grade DCIS. In conclusion, there were no significant differences in copy number for 21 breast cancer related genes between DCIS and adjacent IDC, indicating that DCIS is genetically as advanced as its invasive counterpart. However, high-grade DCIS showed more copy number changes than low/intermediate-grade DCIS with specifically involved genes, supporting a model in which different histological grades of DCIS are associated with distinct genomic changes that progress to IDC in different routes. These high-grade DCIS specific genes may be potential targets for treatment and/or predict progression.",
keywords = "breast cancer, DCIS, IDC, laser microdissection, MLPA",
author = "Moelans, {Cathy B.} and {De Weger}, {Roel A.} and Monsuur, {Hanneke N.} and Maes, {Anoek H J} and {Van Diest}, {Paul J.}",
year = "2010",
doi = "10.3233/ACP-CLO-2010-0546",
language = "English (US)",
volume = "33",
pages = "165--173",
journal = "Analytical Cellular Pathology",
issn = "2210-7177",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma

T2 - A multiplex ligation-dependent probe amplification study

AU - Moelans, Cathy B.

AU - De Weger, Roel A.

AU - Monsuur, Hanneke N.

AU - Maes, Anoek H J

AU - Van Diest, Paul J.

PY - 2010

Y1 - 2010

N2 - Ductal carcinoma in situ (DCIS) accounts for approximately 20% of mammographically detected breast cancers. Although DCIS is generally highly curable, some women with DCIS will develop life-threatening invasive breast cancer, but the determinants of progression to infiltrating ductal cancer (IDC) are largely unknown. In the current study, we used multiplex ligation-dependent probe amplification (MLPA), a multiplex PCR-based test, to compare copy numbers of 21 breast cancer related genes between laser-microdissected DCIS and adjacent IDC lesions in 39 patients. Genes included in this study were ESR1, EGFR, FGFR1, ADAM9, IKBKB, PRDM14, MTDH, MYC, CCND1, EMSY, CDH1, TRAF4, CPD, MED1, HER2, CDC6, TOP2A, MAPT, BIRC5, CCNE1 and AURKA. There were no significant differences in copy number for the 21 genes between DCIS and adjacent IDC. Low/intermediate-grade DCIS showed on average 6 gains/amplifications versus 8 in high-grade DCIS (p=0.158). Furthermore, alterations of AURKA and CCNE1 were exclusively found in high-grade DCIS, and HER2, PRDM14 and EMSY amplification was more frequent in high-grade DCIS than in low/intermediate-grade DCIS. In contrast, the average number of alterations in low/intermediate and high-grade IDC was similar, and although EGFR alterations were exclusively found in high-grade IDC compared to low/intermediate-grade IDC, there were generally fewer differences between low/intermediate-grade and high-grade IDC than between low/intermediate-grade and high-grade DCIS. In conclusion, there were no significant differences in copy number for 21 breast cancer related genes between DCIS and adjacent IDC, indicating that DCIS is genetically as advanced as its invasive counterpart. However, high-grade DCIS showed more copy number changes than low/intermediate-grade DCIS with specifically involved genes, supporting a model in which different histological grades of DCIS are associated with distinct genomic changes that progress to IDC in different routes. These high-grade DCIS specific genes may be potential targets for treatment and/or predict progression.

AB - Ductal carcinoma in situ (DCIS) accounts for approximately 20% of mammographically detected breast cancers. Although DCIS is generally highly curable, some women with DCIS will develop life-threatening invasive breast cancer, but the determinants of progression to infiltrating ductal cancer (IDC) are largely unknown. In the current study, we used multiplex ligation-dependent probe amplification (MLPA), a multiplex PCR-based test, to compare copy numbers of 21 breast cancer related genes between laser-microdissected DCIS and adjacent IDC lesions in 39 patients. Genes included in this study were ESR1, EGFR, FGFR1, ADAM9, IKBKB, PRDM14, MTDH, MYC, CCND1, EMSY, CDH1, TRAF4, CPD, MED1, HER2, CDC6, TOP2A, MAPT, BIRC5, CCNE1 and AURKA. There were no significant differences in copy number for the 21 genes between DCIS and adjacent IDC. Low/intermediate-grade DCIS showed on average 6 gains/amplifications versus 8 in high-grade DCIS (p=0.158). Furthermore, alterations of AURKA and CCNE1 were exclusively found in high-grade DCIS, and HER2, PRDM14 and EMSY amplification was more frequent in high-grade DCIS than in low/intermediate-grade DCIS. In contrast, the average number of alterations in low/intermediate and high-grade IDC was similar, and although EGFR alterations were exclusively found in high-grade IDC compared to low/intermediate-grade IDC, there were generally fewer differences between low/intermediate-grade and high-grade IDC than between low/intermediate-grade and high-grade DCIS. In conclusion, there were no significant differences in copy number for 21 breast cancer related genes between DCIS and adjacent IDC, indicating that DCIS is genetically as advanced as its invasive counterpart. However, high-grade DCIS showed more copy number changes than low/intermediate-grade DCIS with specifically involved genes, supporting a model in which different histological grades of DCIS are associated with distinct genomic changes that progress to IDC in different routes. These high-grade DCIS specific genes may be potential targets for treatment and/or predict progression.

KW - breast cancer

KW - DCIS

KW - IDC

KW - laser microdissection

KW - MLPA

UR - http://www.scopus.com/inward/record.url?scp=79952568983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952568983&partnerID=8YFLogxK

U2 - 10.3233/ACP-CLO-2010-0546

DO - 10.3233/ACP-CLO-2010-0546

M3 - Article

C2 - 20978320

AN - SCOPUS:79952568983

VL - 33

SP - 165

EP - 173

JO - Analytical Cellular Pathology

JF - Analytical Cellular Pathology

SN - 2210-7177

IS - 3-4

ER -